• Dong-A Pharmaceutical subsidiary Dong-A ST received South Korean approval for type 2 diabetes combination drug Sugaempa on Oct. 30, 2026.
• The Ministry of Food and Drug Safety granted authorization following a March 13, 2026, application.
• Approved formulations combine evogliptin 5 mg with empagliflozin at either 10 mg or 25 mg.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dong-A Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800944), on October 30, 2026, and is solely responsible for the information contained therein.